Five-year DFS rates was 77.3% for patients with STAT3-positive tumors versus only 42.7% for patients with STAT3-negative tumors (Figure 4C), even though patients with STAT3 positive tumors had a more advanced tumor stage in our cohort (Supplementary Table 1). The gene discussed is STAT3; the disease is neoplasm.